HTA
Are Orphan Drugs Still a Licence to Print Money?
July 20 by Andrea CharlesIn this podcast Donald Macarthur, global pharmaceutical business analyst, speaks to Andrea Charles from Pharma IQ, about Pharma's steps into the orphan drug market and whether payers can afford to fun...
Health Technology Assessment Goes Online
June 22 by Pharma IQ NewsPharma IQ is pioneering new HTA discussion platform with launch of the first ever HTA Online event - Global HTA and CER Forum, which will take an innovative form of 12 online session over the course o...
The Potential Benefits of HTA Centralisation
February 24 by Pharma IQIt is quickly becoming clear in the pharmaceutical industry that price and value are two defining issues, with organisations constantly striving to develop optimum strategies for understanding value...
Is the European Harmonisation of HTA Worth Pursuing?
February 23 by Pharmaceuticals & Biotechnology EditorAnsgar Hebborn, Head of the Global Payer & HTA Program Policy at F Hoffmann-La Roche, joins Tim Haïdar from Pharma IQ, to analyse major trends and implications for the research-ba...
Health Technology Assessment: Developing Strategies for Understanding Value-Based Pricing
January 19 by Pharma IQValue-based pricing is one issue which divides those in the pharmaceutical industry and the medical community. Much of this debate centres around how value is defined. This is a subject which has...
Where is Health Technology Assessment Going?
November 04 by Pharma IQChrissie Fletcher, Director and Head of International Biostatistics at Amgen, talks to Helen Winsor from Pharma IQ, about innovation in clinical design, analysis and reporting. Fletcher disc...
Health Technology Assessment Climbs Up the European Agenda due to Lack of Resources
November 03 by Andrea CharlesHealth Technology Assessment (HTA) is climbing up the agenda in many European countries due to increasing healthcare costs and budgetary pressures. Limited resource According to the European Society...
Top Tips for Preparing Health Technology Submissions
July 22 by Pharma IQDr. Franz Hessel, Director of International Health Economics Outcomes Research at Abbott, talks to Andrea Charles from Pharma IQ, about the approaches authorities in leading pharmaceutical m...
HTA: Past, Present and Future
March 29 by Pharmaceuticals & Biotechnology EditorAnsgar Hebborn, Head of the Global Payer & HTA Program Policy at F Hoffmann-La Roche, joins Pharma IQ to analyse major trends and implications for the research-based pharmaceutical industry....